Skip to main content
Genmab A/S (ETR:GE9)
Germany flag Germany · Delayed Price · Currency is EUR
223.60
-2.70 (-1.19%)
Last updated: Apr 28, 2026, 9:23 AM CET

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of EUR 13.88 billion. The enterprise value is 17.04 billion.

Market Cap 13.88B
Enterprise Value 17.04B

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date May 7, 2026
Ex-Dividend Date n/a

Share Statistics

Current Share Class 61.39M
Shares Outstanding n/a
Shares Change (YoY) -3.04%
Shares Change (QoQ) +1.68%
Owned by Insiders (%) 1.18%
Owned by Institutions (%) 60.65%
Float 60.66M

Valuation Ratios

The trailing PE ratio is 16.93 and the forward PE ratio is 20.37.

PE Ratio 16.93
Forward PE 20.37
PS Ratio 4.38
PB Ratio 2.79
P/TBV Ratio n/a
P/FCF Ratio 14.19
P/OCF Ratio 13.75
PEG Ratio n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.32, with an EV/FCF ratio of 17.42.

EV / Earnings 20.78
EV / Sales 5.38
EV / EBITDA 15.32
EV / EBIT 16.02
EV / FCF 17.42

Financial Position

The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.93.

Current Ratio 2.02
Quick Ratio 2.01
Debt / Equity 0.93
Debt / EBITDA 4.15
Debt / FCF 4.72
Interest Coverage 20.49

Financial Efficiency

Return on equity (ROE) is 17.53% and return on invested capital (ROIC) is 16.61%.

Return on Equity (ROE) 17.53%
Return on Assets (ROA) 8.10%
Return on Invested Capital (ROIC) 16.61%
Return on Capital Employed (ROCE) 10.92%
Weighted Average Cost of Capital (WACC) n/a
Revenue Per Employee 1.07M
Profits Per Employee 275,879
Employee Count 2,973
Asset Turnover 0.39
Inventory Turnover 17.63

Taxes

In the past 12 months, Genmab has paid 205.26 million in taxes.

Income Tax 205.26M
Effective Tax Rate 20.02%

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average 236.79
200-Day Moving Average n/a
Relative Strength Index (RSI) 38.83
Average Volume (20 Days) 93

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Genmab had revenue of EUR 3.17 billion and earned 820.19 million in profits. Earnings per share was 13.09.

Revenue 3.17B
Gross Profit 2.97B
Operating Income 1.06B
Pretax Income 1.03B
Net Income 820.19M
EBITDA 1.10B
EBIT 1.06B
Earnings Per Share (EPS) 13.09

Balance Sheet

The company has 1.46 billion in cash and 4.62 billion in debt, giving a net cash position of -3.16 billion.

Cash & Cash Equivalents 1.46B
Total Debt 4.62B
Net Cash -3.16B
Net Cash Per Share n/a
Equity (Book Value) 4.98B
Book Value Per Share 80.82
Working Capital 1.24B

Cash Flow

In the last 12 months, operating cash flow was 1.01 billion and capital expenditures -31.51 million, giving a free cash flow of 978.60 million.

Operating Cash Flow 1.01B
Capital Expenditures -31.51M
Depreciation & Amortization 34.15M
Net Borrowing 4.68B
Free Cash Flow 978.60M
FCF Per Share n/a

Margins

Gross margin is 93.60%, with operating and profit margins of 33.60% and 25.89%.

Gross Margin 93.60%
Operating Margin 33.60%
Pretax Margin 32.37%
Profit Margin 25.89%
EBITDA Margin 34.68%
EBIT Margin 33.60%
FCF Margin 30.89%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield 3.04%
Shareholder Yield 3.04%
Earnings Yield 5.91%
FCF Yield 7.05%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Genmab has an Altman Z-Score of 2.48 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.48
Piotroski F-Score 4